In December, the European Commission approved the expansion of the indication for Roche's medicinal product Kadcyla, which contains the active substance trastuzumab emtansine. This expansion makes adjuvant treatment accessible to a much larger number of patients with early HER2-positive breast cancer and reduces the likelihood of disease recurrence or progression.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
